High la (HLA‐DR) and low CD11b (Mo1) expression may predict early conversion to leukemia in myelodysplastic syndromes

American Journal of Hematology

Volumn 43, Issue 3, 1993, Pages 165-171

  Mittelman, Moshe ^a   Karcher, Donald S ^a   Kammerman, Lisa A ^a   Lessin, Lawrence S ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

acute nonlymphoblastic leukemia; immunochemistry; monoclonal antibodies; myelomonocytic differentiation antigens

Indexed keywords

CD11 ANTIGEN; CD11B ANTIGEN; HLA DR ANTIGEN; IA ANTIGEN;

ACUTE NONLYMPHOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; BONE MARROW CELLS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HLA-DR ANTIGENS; HUMAN; LEUKEMIA; MACROPHAGE-1 ANTIGEN; MALE; MIDDLE AGE; MYELODYSPLASTIC SYNDROMES; PHENOTYPE; PROGNOSIS;

EID: 0027308996     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.2830430302     Document Type: Article

References (34)

1. Myelodysplastic syndromes: Pathogenesis, functional abnormalities, and clinical implications
2. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases
3. Myelodysplastic syndromes (preleukemia)
4. Myelodysplasia (preleukemia)
5. The French‐American‐British (FAB) Co‐operative Group: Protocols for the classification of the myelodysplastic syndrome
6. Dysmyelopoietic syndromes. A search for prognostic factors in 193 patients
7. Joint report of the myeloid section of The Second International Workshop and Conference of Human Leukocyte Differentiation Antigens
8. Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies
9. Expression of la‐like antigens on human granulocytes during early phases of differentiation
10. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia
11. The use of monoclonal antibodies in the characterization of myeloid leukemias
12. A monoclonal antibody reactive with human peripheral blood monocytes
13. Antigens on human monocytes identified by monoclonal antibodies
14. Analysis of antigenic determinants on human monocytes and macrophages
15. Surface marker analysis of acute myeloblastic leukemia: Identification of differentiation associated phenotypes
16. Immunologic classification of leukemia and lymphoma
17. Granulocyte‐macrophage colony stimulating factor induces the expression of CD11b surface adhesion molecule on human granulocytes in vivo
18. 1/MAC‐1) and the p150.95 molecule
19. Expression of myeloid differentiation antigens on normal and malignant myeloid cells
20. Expression of normal myeloid associated antigens by acute leukemia cells
21. Heterogeneity of clonogenic cells in acute myeloblastic leukemia
22. Molecular cloning, expression and chromosomal localization of a human gene encoding a 67 kD myeloid differentiation antigen (CD33)
23. Chromosomes in preleukemia
24. Nonparametric estimation from incomplete observations
25. Differentiation patterns in the blastic phase of chronic myeloid leukemias
26. Contribution of immunophenotype to the classification and differential diagnosis of acute leukemia
27. Surface marker analysis in acute myeloid leukemia and correlation with FAB classification
28. Diagnostic and prognostic utility of cell surface markers in acute nonlymphocytic leukemia
29. Granulocyte and monocyte surface membrane markers in the myelodysplastic syndromes
30. Myeloid cell surface phenotype in myelodysplasia: Evidence for abnormal persistence of an early myeloid differentiation antigen
31. + cells in myelodysplastic syndromes: An adverse prognostic feature
32. Expression of myeloid differentiation antigens on myeloblasts in bone marrow of patients with myelodysplastic syndromes
33. Further characterization of human myeloid antigens (gp. 60,95; gp. 150; gp. 67): Investigation of epitopic heterogeneity and non‐haematopoietic distribution using panels of monoclonal antibodies belonging to CD11b. CD13 and CD33